首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   99540篇
  免费   7170篇
  国内免费   321篇
耳鼻咽喉   1274篇
儿科学   2535篇
妇产科学   2310篇
基础医学   12445篇
口腔科学   2062篇
临床医学   9727篇
内科学   21726篇
皮肤病学   1069篇
神经病学   8655篇
特种医学   3359篇
外国民族医学   3篇
外科学   16239篇
综合类   1403篇
现状与发展   1篇
一般理论   75篇
预防医学   7870篇
眼科学   2655篇
药学   6346篇
中国医学   142篇
肿瘤学   7135篇
  2023年   363篇
  2022年   587篇
  2021年   1645篇
  2020年   880篇
  2019年   1586篇
  2018年   1903篇
  2017年   1399篇
  2016年   1552篇
  2015年   1834篇
  2014年   2726篇
  2013年   4318篇
  2012年   6185篇
  2011年   6454篇
  2010年   3618篇
  2009年   3343篇
  2008年   6124篇
  2007年   6817篇
  2006年   6517篇
  2005年   6662篇
  2004年   6498篇
  2003年   6115篇
  2002年   6108篇
  2001年   788篇
  2000年   541篇
  1999年   771篇
  1998年   1283篇
  1997年   1139篇
  1996年   965篇
  1995年   972篇
  1994年   853篇
  1993年   744篇
  1992年   567篇
  1991年   514篇
  1990年   450篇
  1989年   467篇
  1988年   439篇
  1987年   455篇
  1986年   450篇
  1985年   513篇
  1984年   716篇
  1983年   757篇
  1982年   978篇
  1981年   917篇
  1980年   868篇
  1979年   449篇
  1978年   532篇
  1977年   581篇
  1976年   491篇
  1975年   429篇
  1974年   341篇
排序方式: 共有10000条查询结果,搜索用时 328 毫秒
21.
22.
23.
24.
PurposeCongenital high airway obstruction syndrome (CHAOS) is a devastating fetal condition of complete airway discontinuity resulting in significant hydrops and extreme lung hyperplasia. It is universally fatal with survival reported only in the rare spontaneous fistulization or EXIT intervention (Ex Utero Intrapartum Treatment). Even in these cases, mortality remains high, and current investigations are targeting prenatal interventions. This report describes our experience with management and fetal interventions for CHAOS, including laser laryngotomy.MethodsWe retrospectively reviewed all patients diagnosed with CHAOS at a single academic institution between 2006 and 2017.ResultsFifteen patients were identified. Eight had obstruction at the trachea and seven at the larynx. In the laryngeal obstructions, three expired shortly after birth, and one survived after spontaneous fistulization and subsequent EXIT to tracheostomy. The remaining three underwent in-utero treatment with laser laryngotomy. One had preterm premature rupture of membranes (PPROM), delivered 3 days post-operatively, and died. Two underwent EXIT to tracheostomy with one surviving to discharge and is currently 2 years old.ConclusionOur study demonstrates the outcomes of a large series of patients diagnosed with CHAOS. While mortality remains high, options for fetal intervention are being explored to allow alterations in the prenatal natural history and improve postnatal outcomes.Type of StudyRetrospective Treatment Study.Level of EvidenceLevel IV.  相似文献   
25.
26.
27.
28.
29.
30.
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号